NEW YORK, NY / ACCESSWIRE / August 11, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Ocugen, Inc. (NASDAQ:OCGN)

Investors Affected : February 2, 2021 - June 10, 2021

A class action has commenced on behalf of certain shareholders in Ocugen, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/ocugen-inc-loss-submission-form/?id=18445&from=1

CorMedix Inc. (NASDAQ:CRMD)

Investors Affected : July 8, 2020 - May 13, 2021

A class action has commenced on behalf of certain shareholders in CorMedix Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/cormedix-inc-loss-submission-form/?id=18445&from=1

AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)

Investors Affected : November 11, 2019 - July 16, 2021

A class action has commenced on behalf of certain shareholders in AdaptHealth Corp f/k/a DFB Healthcare Acquisitions Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form/?id=18445&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm